New multispecific antibody useful e.g. for activating T cell expressing V beta 17 and treating disease e.g. adrenal cancer and anal cancer, comprises first binding domain binding to V-beta17 and second binding domain binding second target
	GANESHAN R; GREVAL I S; SINGH S; KHANSEN M R
	2020-09-11
专利权人	JANSSEN BIOTECH INC (JOHJ-C)
申请日期	2020-09-11
专利号	RU2024130711-A
成果简介	NOVELTY - A multispecific antibody comprising (a) a first binding domain that binds to Vβ 17 and (b) a second binding domain that binds a second target that is not Vβ 17, is new. The multispecific antibody comprises heavy chain variable region (VH) comprising complementarity determining region (CDR)1, CDR2 and CDR3 and light chain variable region (VL) comprising CDR1, CDR2 and CDR3, where (i) the VH comprises an amino acid sequence of SEQ ID NO: 21 (not provided in the specification) and the VL comprises an amino acid sequence of SEQ ID NO: 677 (not provided in the specification), (ii) the VH comprises an amino acid sequence of SEQ ID NO: 77 (not provided in the specification) and the VL comprises an amino acid sequence of SEQ ID NO: 78 (not provided in the specification) or (iii) the VH comprises an amino acid sequence of SEQ ID NO: 79 (not provided in the specification)and the VL comprises an amino acid sequence of SEQ ID NO: 80 (not provided in the specification). USE - The multispecific antibody is useful in pharmaceutical composition for activating a T cell expressing Vβ 17, directing a T cell expressing Vβ 17 to a target cell, inhibiting growth or proliferation of a target cell, eliminating a target cell in a subject and treating a disease in a subject. The target cell is a cancer cell chosen from an adrenal cancer cell, an anal cancer cell, an appendix cancer cell, a bile duct cancer cell, a bladder cancer cell, a bone cancer cell, a brain cancer cell, a breast cancer cell, a cervical cancer cell, a colorectal cancer cell, an esophageal cancer cell, a gallbladder cancer cell, a gestational trophoblastic disease cell, a head and neck cancer cell, a bowel cancer cell, a kidney cancer cell, a liver cancer cell, a lung cancer cell, a melanoma cell, a mesothelioma cell, a neuroendocrine tumor cell, an oral cancer cell, an ovarian cancer cell, a pancreatic cancer cell, a prostate cancer cell, a paranasal sinus cancer cell, a skin cancer cell, a soft tissue sarcoma cell, a spinal cancer cell, a gastric cancer cell, a testicular cancer cell, a throat cancer cell, a thyroid cancer cell, a uterine cancer cell, and an endometrial, vaginal or vulvar cancer cell. The cancer cell expresses CD 123, DLL3 and/or PSMA. The disease is chosen from adrenal cancer, anal cancer, appendiceal cancer, bile duct cancer, bladder cancer, brain cancer, breast cancer, cervical cancer, colorectal cancer, esophageal cancer, gallbladder cancer, gestational trophoblastic disease, head and neck cancer, bowel cancer, kidney cancer, liver cancer, lung cancer, melanoma, mesothelioma, multiple myeloma, oral cancer, ovarian cancer, prostate cancer, paranasal sinus cancer, soft tissue sarcoma, spinal cancer, gastric cancer, testicular cancer, throat cancer, thyroid cancer, uterine cancer, vaginal cancer and vulvar cancer (all claimed). DETAILED DESCRIPTION - A multispecific antibody comprising (a) a first binding domain that binds to Vβ 17 and (b) a second binding domain that binds a second target that is not Vβ 17, is new. The multispecific antibody comprises heavy chain variable region (VH) comprising complementarity determining region (CDR)1, CDR2 and CDR3 and light chain variable region (VL) comprising CDR1, CDR2 and CDR3, where (i) the VH comprises an amino acid sequence of SEQ ID NO: 21 and the VL comprises an amino acid sequence of SEQ ID NO: 677, (ii) the VH comprises an amino acid sequence of SEQ ID NO: 77 and the VL comprises an amino acid sequence of SEQ ID NO: 78, (iii) the VH comprises an amino acid sequence of SEQ ID NO: 79 and the VL comprises an amino acid sequence of SEQ ID NO: 80, (iv) the VH comprises an amino acid sequence of SEQ ID NO: 81 and the VL comprises an amino acid sequence of SEQ ID NO: 82, (v) the VH comprises an amino acid sequence of SEQ ID NO: 83 and the VL comprises an amino acid sequence of SEQ ID NO: 84, (vi) the VH comprises an amino acid sequence of SEQ ID NO: 85 and the VL comprises an amino acid sequence of SEQ ID NO: 86, (vii) the VH comprises an amino acid sequence of SEQ ID NO: 87 and the VL comprises an amino acid sequence of SEQ ID NO: 88, (viii) the VH comprises an amino acid sequence of SEQ ID NO: 1000 and the VL comprises an amino acid sequence of SEQ ID NO: 1001, (ix) the VH comprises an amino acid sequence of SEQ ID NO: 1032 and the VL comprises an amino acid sequence of SEQ ID NO: 1033, (x) the VH comprises an amino acid sequence of SEQ ID NO: 1064 and the VL comprises an amino acid sequence of SEQ ID NO: 1065, (xi) the VH comprises an amino acid sequence of SEQ ID NO: 1096 and the VL comprises an amino acid sequence of SEQ ID NO: 1097, or (xii) the VH comprises an amino acid sequence of SEQ ID NO: 1128 and the VL comprises an amino acid sequence of SEQ ID NO: 1129. Sequences not provided in the specification. INDEPENDENT CLAIMS are included for the following: pharmaceutical composition comprising the antibody and carrier; method for producing the pharmaceutical composition involves combining the antibody with carrier; nucleic acid encoding the antibody; vector or host cell comprising the nucleic acid; and kit comprising the antibody and a package for the antibody.
IPC 分类号	C07K-016/28
国家	俄罗斯
专业领域	生物科学
语种	英语
成果类型	专利
文献类型	科技成果
条目标识符	http://119.78.100.226:8889/handle/3KE4DYBR/13148
专题	中国科学院新疆生态与地理研究所
作者单位	JANSSEN BIOTECH INC (JOHJ-C)
推荐引用方式 GB/T 7714	GANESHAN R,GREVAL I S,SINGH S,et al. New multispecific antibody useful e.g. for activating T cell expressing V beta 17 and treating disease e.g. adrenal cancer and anal cancer, comprises first binding domain binding to V-beta17 and second binding domain binding second target. RU2024130711-A[P]. 2020.

条目包含的文件
条目无相关文件。

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。